R. Masotti

Safety and immunogenicity of a SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in healthy adults: interim findings from a phase 2, randomised, dose-finding, multi-centre study

N. Michael, R. Canter, N. Rouphael, 2021, medRxiv.

Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 Protein Vaccine

Kwaku Poku Asante, S. Gurunathan, N. Michael, 2022, medRxiv.

Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines

S. Gurunathan, N. Michael, S. Sridhar, 2022, medRxiv.

Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study

N. Michael, N. Rouphael, C. Diazgranados, 2022, The Lancet Infectious Diseases.

Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging study

I. Frank, P. Goepfert, S. Gurunathan, 2021, The Lancet Infectious Diseases.

Efficacy of a monovalent (D614) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, multi-country study

Kwaku Poku Asante, D. Follmann, M. Robb, 2023, eClinicalMedicine.